COVID-19 Study Reveals Promising Therapeutic Strategy with Trispecific Fusion Protein

Strategic Insights -

Research conducted by a team of scientists at Shanxi Agricultural University has led to the development of a trispecific fusion protein that targets COVID-19 with promising results. The study focused on the severe consequences of COVID-19 infections, particularly among elderly individuals and those with underlying medical conditions. The research identified elevated levels of interleukin-6 (IL-6) and tumor necrosis factor (TNF) as independent predictors of disease severity and mortality. In response, a series of bifunctional and trifunctional decoy receptor fusion proteins were created, which effectively blocked pro-inflammatory signaling pathways, significantly reducing pulmonary pathology in a mouse model of acute lung inflammation.

Key Takeaways:

  • The COVID-19 study demonstrated the effectiveness of a trispecific fusion protein in reducing pulmonary pathology in a mouse model of acute lung inflammation.
  • The trispecific fusion protein targets and blocks pro-inflammatory signaling pathways, offering a promising therapeutic strategy for severe COVID-19.
  • Elevated levels of IL-6 and TNF are independent predictors of disease severity and mortality in COVID-19 patients.
  • Five mutations (T27F, K31Y, L79W, R273Q, and N330Y) were introduced into the ACE2 domain to enhance its binding affinity and neutralizing activity against a broad range of SARS-CoV-2 variants.
  • The bifunctional and trifunctional decoy receptor fusion proteins effectively dampened IL-6- and TNF-mediated inflammation in the mouse model.
  • The research suggests that this novel therapeutic approach could be applied to emerging viral infections.

Statistics:

  • 5 mutations were introduced into the ACE2 domain to enhance its binding affinity and neutralizing activity against SARS-CoV-2 variants.
  • The bifunctional and trifunctional decoy receptor fusion proteins effectively blocked pro-inflammatory signaling pathways, significantly reducing IL-6- and TNF-mediated inflammation.

Sources:

  • "Development of a trispecific fusion protein based on angiotensin-converting enzyme 2, glycoprotein 130, and tumor necrosis factor receptor 2 as a promising therapeutic for COVID-19." (Molecular Biomedicine, 2025;6(1):74)
  • Proteomics Weekly. October 27, 2025; p 95 (New COVID-19 Findings from Shanxi Agricultural University Outlined).